Security key
55287L101
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 32,941,714
- Total 13F value
- $606,485,118
- Share change
- +2,632,244
- SEC-reported price per share
- $18.43
- Number of holders
- 63
- Value change
- +$45,787,522
- Number of buys
- 41
- Number of sells
- 23
- Shares outstanding
- 47,785,109
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
63
Top holders
10
MBX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
MBX Biosciences, Inc. SEC filings
MBX Biosciences, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 55287L101
Recent filing periods:
Ownership snapshot
Top reported holders of MBX - MBX Biosciences, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Frazier Life Sciences Man...
Disclosed value leader
Frazier Life Sciences Man...
Comparable rows
15/15
Latest evidence
30 Sep 2024
13F
Lead comparable stake: 13%
Showing 1-6 of 15 holder rows.
Quick read
Frazier Life Sciences Management, L.P. leads the comparable SEC ownership view at 13%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Frazier Life Sciences Management, L.P.'s linked filing trail.
Comparable ownership
Top 5
Frazier Life Sciences Management,...
13%
ORBIMED ADVISORS LLC
8%
NEA Management Company, LLC
7.6%
Deep Track Capital, LP
6.3%
WELLINGTON MANAGEMENT GROUP LLP
6.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. |
13F
Company
|
13%
|
$155,499,315
5,985,347 shares
|
— | 30 Sep 2024 |
| ORBIMED ADVISORS LLC |
13F
Company
|
8%
|
$99,041,346
3,812,215 shares
|
— | 30 Sep 2024 |
| NEA Management Company, LLC |
13F
Company
|
7.6%
|
$93,904,346
3,614,486 shares
|
— | 30 Sep 2024 |
| Deep Track Capital, LP |
13F
Company
|
6.3%
|
$78,431,931
3,018,935 shares
|
— | 30 Sep 2024 |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
Company
|
6.1%
|
$74,261,258
2,937,853 shares
|
— | 30 Sep 2024 |
| NVP Associates, LLC |
13F
Company
|
4.5%
|
$55,501,983
2,136,335 shares
|
— | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
63
Shares
32,941,714
Rows available
63
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
45
Q4 2024 holders
63
Holder diff
18
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend